-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-108 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-108 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-108 in Triple-Negative Breast Cancer (TNBC) Drug Details: LM-108...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-302 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LM-302 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: LM-302 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Solid Tumor Drug Details: Nedisertib (M-3814, MSC-2490484A) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Neuroendocrine Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Neuroendocrine Tumors Drug Details: Nedisertib (M-3814, MSC-2490484A) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Metastatic Renal Cell Carcinoma Drug Details: Nedisertib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Diffuse Large B-Cell Lymphoma Drug Details: AT-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pivekimab Sunirine in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pivekimab Sunirine in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pivekimab Sunirine in Relapsed Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LM-302 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LM-302 in Solid Tumor Drug Details: LM-302 is under development for the treatment of CLDN18.2-positive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Peltopepimut-s in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Peltopepimut-s in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peltopepimut-s in Oropharyngeal Cancer Drug Details: Peltopepimut-s (ISA-101) is under development for...